BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 17909067)

  • 21. Aggressive inherited and sporadic medullary thyroid carcinomas display similar oncogenic pathways.
    Ameur N; Lacroix L; Roucan S; Roux V; Broutin S; Talbot M; Dupuy C; Caillou B; Schlumberger M; Bidart JM
    Endocr Relat Cancer; 2009 Dec; 16(4):1261-72. PubMed ID: 19675075
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Occurrence of the Cys611Tyr mutation and a novel Arg886Trp substitution in the RET proto-oncogene in multiple endocrine neoplasia type 2 families and sporadic medullary thyroid carcinoma cases originating from the central region of Portugal.
    Prazeres HJ; Rodrigues F; Figueiredo P; Naidenov P; Soares P; Bugalho MJ; Lacerda M; Campos B; Martins TC
    Clin Endocrinol (Oxf); 2006 Jun; 64(6):659-66. PubMed ID: 16712668
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Familial associations in medullary thyroid carcinoma with Hirschsprung disease: the role of the RET-C620 "Janus" genetic variation.
    Moore SW; Zaahl M
    J Pediatr Surg; 2010 Feb; 45(2):393-6. PubMed ID: 20152359
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluating new candidate SNPs as low penetrance risk factors in sporadic breast cancer: a two-stage Spanish case-control study.
    Vega A; Salas A; Milne RL; Carracedo B; Ribas G; Ruibal A; de León AC; González-Hernández A; Benítez J; Carracedo A
    Gynecol Oncol; 2009 Jan; 112(1):210-4. PubMed ID: 18950845
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The RET functional variant c 587T>C is not associated with susceptibility to sporadic medullary thyroid cancer.
    Fernández RM; Sánchez-Mejías A; Navarro E; López-Alonso M; Antiñolo G; Borrego S
    Thyroid; 2009 Sep; 19(9):1017-8. PubMed ID: 19678735
    [No Abstract]   [Full Text] [Related]  

  • 26. In silico and in vitro analysis of rare germline allelic variants of RET oncogene associated with medullary thyroid cancer.
    Cosci B; Vivaldi A; Romei C; Gemignani F; Landi S; Ciampi R; Tacito A; Molinaro E; Agate L; Bottici V; Cappagli V; Viola D; Piaggi P; Vitti P; Pinchera A; Elisei R
    Endocr Relat Cancer; 2011 Oct; 18(5):603-12. PubMed ID: 21810974
    [TBL] [Abstract][Full Text] [Related]  

  • 27. RET mutation status in medullary thyroid cancer(MTC) patients and the significance of genetic screening for mutations in their immediate relatives--a preliminary report.
    Menon MM; Simha MR
    Indian J Pathol Microbiol; 2005 Apr; 48(2):161-5. PubMed ID: 16758654
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In vitro transforming potential, intracellular signaling properties, and sensitivity to a kinase inhibitor (sorafenib) of RET proto-oncogene variants Glu511Lys, Ser649Leu, and Arg886Trp.
    Prazeres H; Couto JP; Rodrigues F; Vinagre J; Torres J; Trovisco V; Martins TC; Sobrinho-Simões M; Soares P
    Endocr Relat Cancer; 2011 Aug; 18(4):401-12. PubMed ID: 21551259
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A common haplotype at the 5' end of the RET proto-oncogene, overrepresented in Hirschsprung patients, is associated with reduced gene expression.
    Griseri P; Bachetti T; Puppo F; Lantieri F; Ravazzolo R; Devoto M; Ceccherini I
    Hum Mutat; 2005 Feb; 25(2):189-95. PubMed ID: 15643606
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Early malignant progression of hereditary medullary thyroid cancer.
    Machens A; Niccoli-Sire P; Hoegel J; Frank-Raue K; van Vroonhoven TJ; Roeher HD; Wahl RA; Lamesch P; Raue F; Conte-Devolx B; Dralle H;
    N Engl J Med; 2003 Oct; 349(16):1517-25. PubMed ID: 14561794
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [RET and GFRA1 germline polymorphisms in medullary thyroid cancer patients].
    Severskaia NV; Saenko VA; Il'in AA; Chebotareva IV; Rumiantsev PO; Isaev PA; Medvedev VS; Iasmita S
    Mol Biol (Mosk); 2006; 40(3):425-35. PubMed ID: 16813162
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The frequency of selected polymorphic variants of the RET gene in patients with medullary thyroid carcinoma and in the general population of central Poland.
    Sromek M; Czetwertyńska M; Skasko E; Zielińska J; Czapczak D; Steffen J
    Endocr Pathol; 2010 Sep; 21(3):178-85. PubMed ID: 20521125
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Multiple endocrine neoplasia 2A due to a unique C609S RET mutation presents with pheochromocytoma and reduced penetrance of medullary thyroid carcinoma.
    Kinlaw WB; Scott SM; Maue RA; Memoli VA; Harris RD; Daniels GH; Porter DM; Belloni DR; Spooner ET; Ernesti MM; Noll WW
    Clin Endocrinol (Oxf); 2005 Dec; 63(6):676-82. PubMed ID: 16343103
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Germline RET mutations in exons 10 and 11: an Iranian survey of 57 medullary thyroid carcinoma cases.
    Hedayati M; Nabipour I; Rezaei-Ghaleh N; Azizi F
    Med J Malaysia; 2006 Dec; 61(5):564-9. PubMed ID: 17623957
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ancestral RET haplotype associated with Hirschsprung's disease shows linkage disequilibrium breakpoint at -1249.
    Fernandez RM; Boru G; Peciña A; Jones K; López-Alonso M; Antiñolo G; Borrego S; Eng C
    J Med Genet; 2005 Apr; 42(4):322-7. PubMed ID: 15805159
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An in-frame complex germline mutation in the juxtamembrane intracellular domain causing RET activation in familial medullary thyroid carcinoma.
    Cordella D; Muzza M; Alberti L; Colombo P; Travaglini P; Beck-Peccoz P; Fugazzola L; Persani L
    Endocr Relat Cancer; 2006 Sep; 13(3):945-53. PubMed ID: 16954442
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Management of medullary thyroid carcinoma.
    Jiménez C; Hu MI; Gagel RF
    Endocrinol Metab Clin North Am; 2008 Jun; 37(2):481-96, x-xi. PubMed ID: 18502338
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Familial medullary carcinoma prevention, risk evaluation, and RET in children of families with MEN2.
    Moore SW; Appfelstaedt J; Zaahl MG
    J Pediatr Surg; 2007 Feb; 42(2):326-32. PubMed ID: 17270543
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Genomic and Transcriptomic Characterization of Sporadic Medullary Thyroid Carcinoma.
    Qu N; Shi X; Zhao JJ; Guan H; Zhang TT; Wen SS; Liao T; Hu JQ; Liu WY; Wang YL; Huang S; Shi RL; Wang Y; Ji QH
    Thyroid; 2020 Jul; 30(7):1025-1036. PubMed ID: 32031055
    [No Abstract]   [Full Text] [Related]  

  • 40. Genetic risk association of CDKN1A and RET gene SNPs with medullary thyroid carcinoma: Results from the largest MTC cohort and meta-analysis.
    Mishra V; Kowtal P; Rane P; Sarin R
    Cancer Med; 2019 Oct; 8(13):6151-6161. PubMed ID: 31408923
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.